{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:15Z","timestamp":1790678595792,"version":"4.1.0"},"reference-count":272,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:00:00Z","timestamp":1502755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.semcancer.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T23:16:36Z","timestamp":1501629396000},"page":"180-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options"],"prefix":"10.1016","volume":"51","author":[{"given":"Steffen","family":"Koschmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vetrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2017.07.006_bib0005","first-page":"1013","article-title":"Chromosome studies in human leukemia: II. Chronic granulocytic leukemia","volume":"27","author":"Nowell","year":"1961","journal-title":"J.Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0025","first-page":"152","article-title":"The natural history of chronic myelogenous leukemia in the interferon era","volume":"32","author":"Giralt","year":"1995","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0040","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0060","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0065","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0070","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.semcancer.2017.07.006_bib0075","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia","volume":"15","author":"Soverini","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0085","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0090","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0095","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0100","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0105","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0115","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0120","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrm.2016.76","article-title":"Epigenetic control of adult stem cell function","volume":"17","author":"Avgustinova","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gde.2016.01.003","article-title":"The epigenetics of tumour initiation: cancer stem cells and their chromatin","volume":"36","author":"Avgustinova","year":"2016","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrg1748","article-title":"The epigenetic progenitor origin of human cancer","volume":"7","author":"Feinberg","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0140","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrm.2016.166","article-title":"Variants of core histones and their roles in cell fate decisions, development and cancer","volume":"18","author":"Buschbeck","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0150","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc2523","article-title":"OPINION gamma H2AX and cancer","volume":"8","author":"Bonner","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0155","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1349-7006.2009.01172.x","article-title":"Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model","volume":"100","author":"Nagamachi","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0160","doi-asserted-by":"crossref","DOI":"10.1038\/nature07849","article-title":"Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions","volume":"458","author":"Cook","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature07668","article-title":"WSTF regulates the H2A: X DNA damage response via a novel tyrosine kinase activity","volume":"457","author":"Xiao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.leukres.2011.10.007","article-title":"BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks","volume":"36","author":"Falinski","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0175","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1182\/blood-2011-05-352252","article-title":"Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining","volume":"119","author":"Chakraborty","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0180","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0185","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0190","doi-asserted-by":"crossref","first-page":"994","DOI":"10.4161\/cc.5.9.2722","article-title":"ATR-Chk1 axis protects BCR\/ABL leukemia cells from the lethal effect of DNA double-strand breaks","volume":"5","author":"Nieborowska-Skorska","year":"2006","journal-title":"ABBV Cell Cycle"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0195","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0200","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0205","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2141.2005.05873.x","article-title":"P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors","volume":"132","author":"Brusa","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0215","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10495-012-0739-9","article-title":"Increased acetylation of lysine 317\/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage","volume":"17","author":"Kusio-Kobialka","year":"2012","journal-title":"Apoptosis"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tig.2015.11.001","article-title":"H3K9me3-dependent heterochromatin: barrier to cell fate changes","volume":"32","author":"Becker","year":"2016","journal-title":"Trends Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0225","first-page":"14","article-title":"Histone trimethylation at H3K4, H3K9 and H4K 20 correlates with patient survival and tumor recurrence in early-stage colon cancer","author":"Benard","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cas.12166","article-title":"Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo","volume":"104","author":"Yokoyama","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0235","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2141.2008.07134.x","article-title":"IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia","volume":"141","author":"Mancini","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1189\/jlb.0704388","article-title":"Methylation of histones in myeloid leukemias as a potential marker of granulocyte abnormalities","volume":"77","author":"Lukasova","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0245","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/nar\/30.2.475","article-title":"Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases","volume":"30","author":"Vaute","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2011.08830.x","article-title":"Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457","volume":"156","author":"Mancini","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0265","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1101\/gad.219899.113","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Gene Dev."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0270","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0275","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0280","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0285","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","article-title":"Mechanisms of Polycomb gene silencing: knowns and unknowns","volume":"10","author":"Simon","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2016.03.013","article-title":"Emerging roles for Polycomb proteins in cancer","volume":"36","author":"Pasini","year":"2016","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0300","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/fon.10.157","article-title":"Epigenetic factors in cancer development: polycomb group proteins","volume":"7","author":"Piunti","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0305","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.2014.335","article-title":"beta-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR\/ABL H4 acetylation","volume":"111","author":"Qin","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2016.03.012","article-title":"BCR\/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells","volume":"45","author":"Nishioka","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0315","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia-Initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0320","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1179\/1607845412Y.0000000056","article-title":"The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells","volume":"18","author":"Bozkurt","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/gcc.20722","article-title":"SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia","volume":"49","author":"Pizzatti","year":"2010","journal-title":"Gene Chromosome Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0335","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/onc.2010.409","article-title":"BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients","volume":"30","author":"De Carvalho","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0340","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190601186002","article-title":"Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation","volume":"48","author":"Merkerova","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0345","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jcmm.12246","article-title":"BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression","volume":"18","author":"Shen","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0350","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nm.4310","article-title":"Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia","volume":"23","author":"Kesarwani","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0355","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0360","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0365","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/leu.2015.112","article-title":"The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells","volume":"29","author":"Mourgues","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0370","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0375","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0380","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","article-title":"ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells","volume":"12","author":"Karvela","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0385","doi-asserted-by":"crossref","DOI":"10.1186\/1478-811X-9-11","article-title":"Mammalian Sirt1: insights on its biological functions","volume":"9","author":"Rahman","year":"2011","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0390","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0395","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0400","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/onc.2012.83","article-title":"SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0405","doi-asserted-by":"crossref","first-page":"18347","DOI":"10.1074\/jbc.R110.205286","article-title":"DNA methylation and demethylation in mammals","volume":"286","author":"Chen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0410","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/ng1598","article-title":"Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells","volume":"37","author":"Weber","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0415","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/ng1909","article-title":"DNA methylation profiling of human chromosomes 6, 20 and 22","volume":"38","author":"Eckhardt","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0420","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.febslet.2009.04.012","article-title":"CpG islands \u2212 \u2018A rough guide'","volume":"583","author":"Illingworth","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0425","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/nar\/11.3.647","article-title":"Unmethylated domains in vertebrate DNA","volume":"11","author":"Cooper","year":"1983","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0430","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0435","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4161\/cc.4.1.1361","article-title":"Inactivation of tumor suppressor genes \u2212 Choice between genetic and epigenetic routes","volume":"4","author":"Chen","year":"2005","journal-title":"ABBV Cell Cycle"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0440","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0445","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2005.08.011","article-title":"Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses","volume":"123","author":"Chen","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0450","first-page":"1678","article-title":"HIC1 hypermethylation is a late event in hematopoietic neoplasms","volume":"57","author":"Issa","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0455","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2015.329","article-title":"Mtss1 is a critical epigenetically regulated tumor suppressor in CML","volume":"30","author":"Schemionek","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0460","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/2431","article-title":"NRSF\/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis","volume":"20","author":"Chen","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0465","doi-asserted-by":"crossref","first-page":"R665","DOI":"10.1016\/j.cub.2005.08.032","article-title":"Transcriptional regulation: cancer, neurons and the REST","volume":"15","author":"Coulson","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0470","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1038\/onc.2011.411","article-title":"MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma","volume":"31","author":"Fan","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0475","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0480","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrg3594","article-title":"NON-CODING RNA Gene regulation by antisense transcription","volume":"14","author":"Pelechano","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0485","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tig.2005.04.009","article-title":"Transcriptional interference \u2212 a crash course","volume":"21","author":"Shearwin","year":"2005","journal-title":"Trends Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0490","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"Micrornas: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0495","doi-asserted-by":"crossref","DOI":"10.1038\/nature09144","article-title":"A coding-independent function of gene and pseudogene mRNAs regulates tumour biology","volume":"465","author":"Poliseno","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0500","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.molcel.2014.03.045","article-title":"Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance","volume":"54","author":"Denzler","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0505","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molcel.2014.09.018","article-title":"Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition","volume":"56","author":"Bosson","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0510","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0515","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0520","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.critrevonc.2009.05.001","article-title":"MicroRNA and leukemia: tiny molecule, great function","volume":"74","author":"Zhao","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0525","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fgene.2011.00094","article-title":"The beginning of the road for non-Coding RNAs in normal hematopoiesis and hematologic malignancies","volume":"2","author":"Heuston","year":"2011","journal-title":"Front. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0530","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11899-012-0152-z","article-title":"Role of epigenetics in chronic myeloid leukemia","volume":"8","author":"Machova Polakova","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0535","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.12364","article-title":"MicroRNAs in myeloid malignancies","volume":"162","author":"Gordon","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0540","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5507\/bp.2014.029","article-title":"The role of miR-29 family members in malignant hematopoiesis","volume":"158","author":"Kollinerova","year":"2014","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0545","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1089\/ars.2014.6096","article-title":"The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia","volume":"22","author":"Tortorella","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0550","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ddr.21266","article-title":"miRNAs as biomarkers in chronic myelogenous leukemia","volume":"76","author":"Kotagama","year":"2015","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0555","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3892\/or.2015.4456","article-title":"The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)","volume":"35","author":"Di Stefano","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0560","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms14035338","article-title":"Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications","volume":"14","author":"Corrado","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0565","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2011-02-338004","article-title":"Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes","volume":"119","author":"Montecalvo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0570","doi-asserted-by":"crossref","first-page":"S1479","DOI":"10.21037\/tcr.2016.12.40","article-title":"miRNA transported by exosomes: a key machinery in tumor microenvironment mediated chemoresistance","volume":"5","author":"Gagliano","year":"2016","journal-title":"Transl Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0575","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0580","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0585","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/10428190903150847","article-title":"Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib","volume":"50","author":"Dillmann","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0590","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0595","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20020519","article-title":"Crosstalk between BCR\/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells","volume":"196","author":"Ptasznik","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0600","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1476-4598-13-169","article-title":"Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells","volume":"13","author":"Taverna","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0605","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0610","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0615","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2011-06-359232","article-title":"Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells","volume":"119","author":"Sengupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0620","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","article-title":"BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34(+) cells","volume":"116","author":"Rizo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0625","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/S0959-8049(03)00552-5","article-title":"Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase","volume":"39","author":"Nagy","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0630","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3892\/ol.2011.419","article-title":"Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis","volume":"3","author":"Uehara","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0635","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7314\/APJCP.2014.15.1.75","article-title":"DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients","volume":"15","author":"Bodoor","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0640","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2002-09-2834","article-title":"p14ARF, p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia","volume":"101","author":"Kusy","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0645","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1080\/10428190410001714025","article-title":"p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia","volume":"45","author":"Kusy","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0650","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1182\/blood.V95.9.2990.009k08_2990_2992","article-title":"Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications","volume":"95","author":"Nguyen","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0655","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/jnci\/93.19.1465","article-title":"Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells","volume":"93","author":"Nguyen","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0660","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2009.015693","article-title":"Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells","volume":"95","author":"Janssen","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0665","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","article-title":"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia","volume":"6","author":"Jelinek","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0670","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood.V77.11.2431.2431","article-title":"Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia","volume":"77","author":"Nelkin","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0675","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood.V77.11.2435.bloodjournal77112435","article-title":"Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation","volume":"77","author":"Malinen","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0680","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0145-2126(96)00045-8","article-title":"Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients","volume":"20","author":"Mills","year":"1996","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0685","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2008.01178.x","article-title":"Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia","volume":"82","author":"Qian","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0690","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3892\/ol.2014.2677","article-title":"Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients","volume":"9","author":"Celik","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0695","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1073\/pnas.91.22.10722","article-title":"Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia","volume":"91","author":"Zion","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0700","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood.V90.12.4918","article-title":"Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia","volume":"90","author":"Ben-Yehuda","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0705","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V94.7.2452.419k23_2452_2460","article-title":"ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia","volume":"94","author":"Asimakopoulos","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0710","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood.V93.6.2075.406k29_2075_2080","article-title":"Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance","volume":"93","author":"Issa","year":"1999","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2017.07.006_bib0715","first-page":"25","article-title":"The role of methylation in CML","volume":"57","author":"Rachmilewitz","year":"2000","journal-title":"Przegl. Lek."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0720","first-page":"6931","article-title":"ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors","volume":"61","author":"Sun","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0725","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.leu.2402026","article-title":"ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL","volume":"15","author":"Shteper","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0730","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V94.3.1141.415a35d_1141_1142","article-title":"Prognostic significance of c-ABL methylation in chronic myelogenous leukemia: still an open question","volume":"94","author":"Asimakopoulos","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0735","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2016.143","article-title":"Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia","volume":"30","author":"Heller","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0740","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-44","article-title":"A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers","volume":"9","author":"Dunwell","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0745","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34(+) cells","volume":"109","author":"Venturini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0750","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ijlh.12351","article-title":"Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"37","author":"Fallah","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0755","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.gpb.2014.02.001","article-title":"Characterization of miRNomes in acute and chronic myeloid leukemia cell lines","volume":"12","author":"Xiong","year":"2014","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0760","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Machova Polakova","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0765","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0770","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to ST157, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0775","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1073\/pnas.162140299","article-title":"Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop","volume":"99","author":"Roumiantsev","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0780","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3324\/haematol.2009.014712","article-title":"Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"95","author":"Kim","year":"2010","journal-title":"Haematol.\u2014Hematol. J."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0785","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0790","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2217\/epi.15.35","article-title":"Polycomb genes are associated with response to imatinib in chronic myeloid leukemia","volume":"7","author":"Crea","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0795","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"Jose-Eneriz","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0800","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/129715","article-title":"HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients","author":"Elias","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0805","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","article-title":"Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance","volume":"21","author":"Li","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0810","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34(+) cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0815","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0820","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000353391","article-title":"miRNA expression correlated with morphological findings in chronic myeloid leukemia treated with imatinib mesylate","volume":"131","author":"Gebauer","year":"2014","journal-title":"Acta Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0825","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11010-013-1958-2","article-title":"Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia","volume":"390","author":"Zhu","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","article-title":"MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations","volume":"8","author":"San Jose-Eneriz","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0835","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.yexcr.2013.02.002","article-title":"miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR\/ABL1 protein","volume":"319","author":"Li","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0840","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.leukres.2011.03.029","article-title":"MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop","volume":"35","author":"Lopotova","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0845","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.leukres.2011.08.023","article-title":"miRNA-451: a putative predictor marker of Imatinib therapy response in chronic myeloid leukemia","volume":"36","author":"Scholl","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0850","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V114.22.854.854","article-title":"Suppression of bcr-Abl expression in CML by a panel of miRNAs","volume":"114","author":"Iraci","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0855","first-page":"2017","article-title":"Single-cell epigenomic variability reveals functional cancer heterogeneity","author":"Litzenburger","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0860","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2 '-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0865","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0870","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0875","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2012.01.005","article-title":"Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia","volume":"12","author":"Cervera","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0880","doi-asserted-by":"crossref","first-page":"733-","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0885","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0890","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0895","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0900","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0905","doi-asserted-by":"crossref","first-page":"364-","DOI":"10.1038\/ng.2913","article-title":"An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia","volume":"46","author":"Knoechel","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0910","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0915","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0920","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0925","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0930","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0935","doi-asserted-by":"crossref","first-page":"E198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0940","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/leu.2010.236","article-title":"IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis","volume":"25","author":"Soverini","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0945","first-page":"232","article-title":"Somatic mutations in newly-diagnosed chronic myeloid leukemia detected by whole-exome sequencing","volume":"101","author":"Nakaseko","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0950","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0955","first-page":"3","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","author":"Menezes","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0960","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-8722-7-43","article-title":"Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding","volume":"7","author":"Dzikiewicz-Krawczyk","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0965","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00277-008-0603-8","article-title":"BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia","volume":"88","author":"Bhattacharyya","year":"2009","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0970","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.lfs.2011.09.011","article-title":"16-hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells","volume":"89","author":"Lin","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0975","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/aps.2012.9","article-title":"Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3\/Mst1 pathway","volume":"33","author":"Zhang","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0980","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10495-014-0997-9","article-title":"H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib","volume":"19","author":"Dong","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.semcancer.2017.07.006_bib0985","doi-asserted-by":"crossref","first-page":"8479","DOI":"10.1007\/s13277-015-3583-z","article-title":"Zerumbone induces mitochondria-mediated apoptosis via increased calcium, generation of reactive oxygen species and upregulation of soluble histone H2AX in K562 chronic myelogenous leukemia cells","volume":"36","author":"Rajan","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0990","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/aps.2014.132","article-title":"Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.semcancer.2017.07.006_bib0995","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.4161\/epi.29675","article-title":"ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC \u2212100 box in its promoter","volume":"9","author":"Correa","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1000","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjh.12023","article-title":"DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia","volume":"159","author":"Leo","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3892\/ol.2010.208","article-title":"Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients","volume":"2","author":"Koh","year":"2011","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jcb.25010","article-title":"DNA methyltransferase 1 drives transcriptional down-modulation of beta catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia","volume":"116","author":"Leo","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1179\/1607845413Y.0000000081","article-title":"Methylation status of CEBPA gene promoter in chronic myeloid leukemia","volume":"19","author":"Annamaneni","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1020","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1582-4934.2010.01203.x","article-title":"Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia","volume":"15","author":"Samaiya","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-29-54","article-title":"Methylation status of DDIT3 gene in chronic myeloid leukemia","volume":"29","author":"Wang","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1030","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbrc.2015.06.095","article-title":"Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia","volume":"463","author":"Zhou","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1035","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1182\/blood.V91.9.3144","article-title":"Loss of imprinting in disease progression in chronic myelogenous leukemia","volume":"91","author":"Randhawa","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1040","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2002-05-1598","article-title":"JunB gene expression is inactivated by methylation in chronic myeloid leukemia","volume":"101","author":"Yang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1045","first-page":"4984","article-title":"Presence of cell lineage-specific hypomethylated sites in the major breakpoint cluster region","volume":"50","author":"Litz","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1050","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood.V88.6.2241.bloodjournal8862241","article-title":"Aberrant methylation of the major breakpoint cluster region in chronic myeloid leukemia","volume":"88","author":"Litz","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0165-4608(00)00394-0","article-title":"Possible prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset by determining the methylation status of the major breakpoint cluster region","volume":"126","author":"Ge","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1060","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ijc.21584","article-title":"Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia","volume":"118","author":"Agirre","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1065","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1349-7006.2006.00331.x","article-title":"Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3","volume":"97","author":"Yang","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1070","first-page":"179","article-title":"Epigenetic inactivation of PLCD1 in chronic myeloid leukemia","volume":"30","author":"Song","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1075","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.leukres.2007.02.016","article-title":"Epigenetic regulation of PRAME gene in chronic myeloid leukemia","volume":"31","author":"Roman-Gomez","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1080","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.3892\/or.2014.3098","article-title":"Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia","volume":"31","author":"Li","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1085","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.leukres.2009.01.003","article-title":"Methylation status of RASSF1A in patients with chronic myeloid leukemia","volume":"33","author":"Avramouli","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1090","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.leukres.2008.11.013","article-title":"sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia","volume":"33","author":"Pehlivan","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1095","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2141.2003.04660.x","article-title":"Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia","volume":"123","author":"Liu","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1100","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.7314\/APJCP.2014.15.11.4555","article-title":"Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells","volume":"15","author":"Al-Jamal","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12185-012-1106-x","article-title":"Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia","volume":"96","author":"Yang","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-9-41","article-title":"Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia","volume":"9","author":"Rogers","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1089\/gtmb.2012.0530","article-title":"The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia","volume":"17","author":"Chen","year":"2013","journal-title":"Genet. Test. Mol. Biomark."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1006\/bbrc.1997.6592","article-title":"Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl","volume":"234","author":"Wu","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.leukres.2007.07.021","article-title":"Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia","volume":"32","author":"Roman-Gomez","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ajh.20886","article-title":"The SOCS-1 gene methylation in chronic myeloid leukemia patients","volume":"82","author":"Hatirnaz","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1135","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/onc.2014.131","article-title":"A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA","volume":"34","author":"Guo","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1140","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1039\/C6MB00568C","article-title":"Deciphering the cross-talking of human competitive endogenous RNAs in K562 chronic myelogenous leukemia cell line","volume":"12","author":"Sen","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1145","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.7314\/APJCP.2013.14.12.7501","article-title":"Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes","volume":"14","author":"Feng","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1150","doi-asserted-by":"crossref","first-page":"34343","DOI":"10.1074\/jbc.M113.480822","article-title":"Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells","volume":"288","author":"Tadokoro","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1155","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/onc.2012.295","article-title":"Leukemia cell to endothelial cell communication via exosomal miRNAs","volume":"32","author":"Umezu","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1179\/1607845413Y.0000000094","article-title":"Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib","volume":"19","author":"Silveira","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1165","doi-asserted-by":"crossref","first-page":"14117","DOI":"10.1007\/s13277-016-5205-9","article-title":"miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-kappaB target genes","volume":"37","author":"Farhadi","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12079-011-0139-x","article-title":"MicroRNAs 130a\/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML","volume":"5","author":"Suresh","year":"2011","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1175","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2012.07.098","article-title":"Myc induced miR-144\/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562","volume":"425","author":"Liu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1180","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/DDDT.S66812","article-title":"Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely","volume":"8","author":"Ohyashiki","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1185","doi-asserted-by":"crossref","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","article-title":"Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells","volume":"7","author":"Rokah","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.110.066258","article-title":"Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia","volume":"78","author":"Zimmerman","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1195","doi-asserted-by":"crossref","first-page":"e32834","DOI":"10.1371\/journal.pone.0032834","article-title":"miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML)","volume":"7","author":"Fei","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1200","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1166\/jbn.2015.2147","article-title":"Modulating the growth and imatinib sensitivity of chronic myeloid leukemia stem\/progenitor cells with Pllulan\/microRNA nanoparticles in vitro","volume":"11","author":"Ma","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1205","doi-asserted-by":"crossref","DOI":"10.1186\/1755-8166-6-27","article-title":"Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia","volume":"6","author":"Mosakhani","year":"2013","journal-title":"Mol Cytogenet"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1210","doi-asserted-by":"crossref","first-page":"e68442","DOI":"10.1371\/journal.pone.0068442","article-title":"Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1215","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2008.07459.x","article-title":"MIRN199B downregulation in chronic myeloid leukaemia is associated with deletions on der(9)","volume":"144","author":"Albano","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1220","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/leu.2008.154","article-title":"MicroRNAs and deletion of the derivative chromosome 9 in chronic myeloid leukemia","volume":"23","author":"Chaubey","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2014.03.049","article-title":"Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR\/ABL positive CML patients","volume":"542","author":"Joshi","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1230","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"13","author":"Bueno","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1235","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","article-title":"Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib","volume":"37","author":"Shibuta","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1240","doi-asserted-by":"crossref","first-page":"e61858","DOI":"10.1371\/journal.pone.0061858","article-title":"Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1245","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.18632\/oncotarget.2859","article-title":"Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12032-009-9413-7","article-title":"miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines","volume":"28","author":"Gu","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1255","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/13894501113149990185","article-title":"Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells","volume":"14","author":"Seca","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1260","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FPC.0b013e328350012b","article-title":"MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression","volume":"22","author":"Turrini","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1265","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/ijms17040570","article-title":"Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib","volume":"17","author":"Ohyashiki","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1270","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.12339","article-title":"Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors","volume":"105","author":"Nishioka","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1275","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/cgt.2014.44","article-title":"The malignancy suppression role of miR-23a by targeting the BCR\/ABL oncogene in chromic myeloid leukemia","volume":"21","author":"Xishan","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/jir.2012.0062","article-title":"Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia","volume":"33","author":"Lee","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1285","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","author":"Yu","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1290","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1295","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","article-title":"MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein","volume":"356","author":"Hershkovitz-Rokah","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1300","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1038\/srep12460","article-title":"MicroRNA-320a acts as a tumor suppressor by targeting BCR\/ABL oncogene in chronic myeloid leukemia","volume":"5","author":"Xishan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1305","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ijc.28043","article-title":"Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem\/progenitor cells","volume":"133","author":"Babashah","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1310","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"MiR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1315","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2017.01.020","article-title":"The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF\/MEK\/ERK signaling pathway in K-562 cells","volume":"55","author":"Yang","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1320","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12943-015-0465-3","article-title":"MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45alpha","volume":"14","author":"Yang","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1325","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1479-5876-11-265","article-title":"MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1","volume":"11","author":"Zhou","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00277-010-1072-4","article-title":"Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia","volume":"90","author":"Hussein","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","article-title":"Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment","volume":"360","author":"Hershkovitz-Rokah","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1340","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2014-06-581926","article-title":"MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1345","doi-asserted-by":"crossref","first-page":"e115003","DOI":"10.1371\/journal.pone.0115003","article-title":"Identifying validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line","volume":"9","author":"Bhutra","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.07.006_bib1350","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.1007\/s13277-014-2138-z","article-title":"MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin","volume":"35","author":"Kaymaz","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1355","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/18715206113139990108","article-title":"NFkappaB pathway and microRNA-9 and \u221221 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines","volume":"15","author":"de Faria","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.semcancer.2017.07.006_bib1360","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/mmr.2015.4502","article-title":"Analysis of microRNA and gene networks in human chronic myelogenous leukemia","volume":"13","author":"Wang","year":"2016","journal-title":"Mol. Med. Rep."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:37:27Z","timestamp":1760917047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X17301529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":272,"alternative-id":["S1044579X17301529"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.07.006","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}